Posted by Michael Wonder on 04 Jan 2022
Will the Biden administration use ‘march-in’ to protect prostate cancer patients from excessive drug prices?
3 January 2022 - Astellas Pharma, a drug company headquartered in Japan, is charging U.S. patients $156,000 a year for the prostate cancer drug Xtandi (enzalutamide) — more than three to five times what it charges residents of other wealthy countries, and five times more than it charges in Japan.
Adding insult to injury, Xtandi was discovered by scientists at the University of California, Los Angeles, with grants from the National Institutes of Health and the U.S. Army.
